Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | 4.7x - 5.2x | 4.9x |
| Historical Pb Multiple | 4.8x - 7.0x | 5.4x |
| Fair Value | $128.76 - $142.31 | $135.53 |
| Upside | -2.2% - 8.1% | 2.9% |
| Benchmarks | - | Full Ticker |
| CONMED Corporation | - | NYSE:CNMD |
| Becton, Dickinson and Company | - | NYSE:BDX |
| LeMaitre Vascular, Inc. | - | NasdaqGM:LMAT |
| Haemonetics Corporation | - | NYSE:HAE |
| OraSure Technologies, Inc. | - | NasdaqGS:OSUR |
| Abbott Laboratories | - | NYSE:ABT |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| CNMD | BDX | LMAT | HAE | OSUR | ABT | |||
| NYSE:CNMD | NYSE:BDX | NasdaqGM:LMAT | NYSE:HAE | NasdaqGS:OSUR | NYSE:ABT | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | 35.8% | 9.5% | 19.7% | 16.4% | NM- | 29.5% | ||
| 3Y CAGR | 28.4% | 4.0% | 17.8% | 13.9% | NM- | 23.8% | ||
| Latest Twelve Months | 105.4% | 36.5% | 46.3% | 2.8% | -136.3% | 134.2% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 2.4% | 8.3% | 16.1% | 8.4% | -1.7% | 15.3% | ||
| Prior Fiscal Year | 5.2% | 7.6% | 15.6% | 9.9% | 13.2% | 14.2% | ||
| Latest Fiscal Year | 10.1% | 8.4% | 20.0% | 9.0% | -10.5% | 31.8% | ||
| Latest Twelve Months | 10.1% | 8.4% | 20.0% | 9.5% | -10.5% | 31.8% | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | 3.6% | 5.5% | 11.7% | 12.4% | -0.1% | 17.4% | ||
| Prior Fiscal Year | 8.2% | 5.8% | 10.6% | 14.7% | 13.5% | 15.1% | ||
| Latest Twelve Months | 14.7% | 6.8% | 13.9% | 14.1% | -4.6% | 31.0% | ||
| Next Fiscal Year | 13.4% | 15.5% | 14.5% | 22.4% | -5.2% | 18.2% | ||
| Two Fiscal Years Forward | 13.4% | 15.3% | 14.5% | 21.1% | 1.6% | 18.4% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 1.4x | 3.1x | 8.7x | 2.3x | 1.3x | 5.4x | ||
| Price / LTM EPS | 13.9x | 37.6x | 43.6x | 24.3x | -12.7x | 17.1x | ||
| Price / Book | 1.9x | 2.6x | 5.7x | 3.5x | 0.6x | 4.8x | ||
| Price / Fwd Book | 1.7x | 2.3x | 5.2x | 2.9x | 0.6x | 4.4x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | 0.6x | 2.6x | 5.7x | |||||
| Historical P/B Ratio | 4.8x | 5.4x | 7.0x | |||||
| Selected P/B Multiple | 4.7x | 4.9x | 5.2x | |||||
| (x) Book Value | 47,664 | 47,664 | 47,664 | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | CNMD | BDX | LMAT | HAE | OSUR | ABT | |
| Value of Common Equity | 1,836 | 64,904 | 1,921 | 3,166 | 248 | 228,393 | |
| (/) Shares Outstanding | 30.9 | 287.1 | 22.6 | 50.2 | 74.8 | 1,734.3 | |
| Implied Stock Price | 59.40 | 226.04 | 85.16 | 63.02 | 3.32 | 131.69 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 59.40 | 226.04 | 85.16 | 63.02 | 3.32 | 131.69 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |